Emerging Concern: Lidocaine Adulterated “Purple Fentanyl” in the Midwest

Authors

  • Satneet Singh, M.D. KUMC
  • Melissa Perchellet, M.D. KUMC
  • Sophie Troupe, M.D. KUMC
  • Roopa Sethi, M.D. KUMC

DOI:

https://doi.org/10.17161/kjm.vol19.24641

Keywords:

fentanyl, lidocaine, drug combinations, harm reduction, opioid overdose

Downloads

Published

2026-04-16

Issue

Vol. 19 No. 2 (2026): Mar. - Apr.

Section

Commentary

License

Copyright (c) 2026 Satneet Singh, M.D., Melissa Perchellet, M.D., Sophie Troupe, M.D., Roopa Sethi, M.D.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

How to Cite

Singh, S., Perchellet, M., Troupe, S., & Sethi, R. (2026). Emerging Concern: Lidocaine Adulterated “Purple Fentanyl” in the Midwest. Kansas Journal of Medicine, 19(2), 47-48. https://doi.org/10.17161/kjm.vol19.24641